Alexion Pharmaceuticals
ALXN
ALXN was delisted on the 20th of July, 2021.
515 hedge funds and large institutions have $35B invested in Alexion Pharmaceuticals in 2015 Q3 according to their latest regulatory filings, with 41 funds opening new positions, 227 increasing their positions, 169 reducing their positions, and 72 closing their positions.
34% more repeat investments, than reductions
Existing positions increased: 227 | Existing positions reduced: 169
6% less funds holding
Funds holding: 548 → 515 (-33)
12% less capital invested
Capital invested by funds: $39.8B → $35B (-$4.83B)
17% less funds holding in top 10
Funds holding in top 10: 23 → 19 (-4)
43% less first-time investments, than exits
New positions opened: 41 | Existing positions closed: 72
47% less call options, than puts
Call options by funds: $121M | Put options by funds: $228M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$317M |
| 2 |
WRF
Waddell & Reed Financial
Overland Park,
Kansas
|
+$265M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$222M |
| 4 |
Capital Research Global Investors
Los Angeles,
California
|
+$196M |
| 5 |
Jennison Associates
New York
|
+$167M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$229M |
| 2 |
TCIM
TIAA CREF Investment Management
New York
|
-$189M |
| 3 |
JP Morgan Chase
New York
|
-$97.7M |
| 4 |
DKCM
Davidson Kempner Capital Management
New York
|
-$78.1M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$76.5M |
ALXN Hedge Fund Activity: Q3 2015 in Review
515 of the 3,590 institutional investors tracked by Wall St. Rank reported a position in Alexion Pharmaceuticals (ALXN) for Q3 2015, worth a combined $35B — down 12% from $39.8B a quarter earlier.
Sellers outnumbered buyers: 72 funds closed out of ALXN and 41 opened new positions — a net loss of 31 holders — while 169 trimmed existing stakes and 227 added.
The largest buyer was T. Rowe Price Associates, adding an estimated $317M. The largest seller was Millennium Management, cutting an estimated $229M.
- 515 institutional investors held Alexion Pharmaceuticals (ALXN) as of Q3 2015, down from 548 in Q2 2015.
- Funds reported $35B of Alexion Pharmaceuticals stock for Q3 2015, down 12% quarter-over-quarter.
- 41 funds opened new Alexion Pharmaceuticals positions in Q3 2015 and 72 closed out, a net change of -31 holders.
- The largest Alexion Pharmaceuticals buyer in Q3 2015 was T. Rowe Price Associates, an estimated $317M added.
- The largest Alexion Pharmaceuticals seller in Q3 2015 was Millennium Management, an estimated $229M sold.
Based on aggregated 13F filings for Q3 2015.